These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7687728)

  • 1. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.
    Hartman JC; Wall TM; Hullinger TG; Shebuski RJ
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):996-1003. PubMed ID: 7687728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.
    Hartman JC; Hullinger TG; Wall TM; Shebuski RJ
    Eur J Pharmacol; 1993 Apr; 234(2-3):229-36. PubMed ID: 8482328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
    Hartman JC
    Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of nitric oxide synthase prevents myocardial protection by ramiprilat.
    Hartman JC; Kurc GM; Hullinger TG; Wall TM; Sheehy RM; Shebuski RJ
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1071-6. PubMed ID: 7523655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do angiotensin converting enzyme inhibitors limit myocardial infarct size?
    Miki T; Miura T; Shimamoto K; Urabe K; Sakamoto J; Iimura O
    Clin Exp Pharmacol Physiol; 1993 Jun; 20(6):429-34. PubMed ID: 8339466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.
    Wolfrum S; Richardt G; Dominiak P; Katus HA; Dendorfer A
    Br J Pharmacol; 2001 Sep; 134(2):370-4. PubMed ID: 11564655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide.
    Ehring T; Baumgart D; Krajcar M; Hümmelgen M; Kompa S; Heusch G
    Circulation; 1994 Sep; 90(3):1368-85. PubMed ID: 8087948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
    Liu YH; Yang XP; Sharov VG; Sigmon DH; Sabbath HN; Carretero OA
    Hypertension; 1996 Jan; 27(1):7-13. PubMed ID: 8591891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.
    Schriefer JA; Broudy EP; Hassen AH
    J Pharmacol Exp Ther; 2001 Sep; 298(3):970-5. PubMed ID: 11504792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramiprilat attenuates hypoxia/reoxygenation injury to cardiac myocytes via a bradykinin-dependent mechanism.
    Wall TM; Linseman DA; Hartman JC
    Eur J Pharmacol; 1996 Jun; 306(1-3):165-74. PubMed ID: 8813629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The possible role of bradykinin in the antiischemic activity of ACE-inhibitors.
    Martorana PA; Schölkens BA
    Agents Actions Suppl; 1992; 38 ( Pt 3)():98-102. PubMed ID: 1462888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of bradykinin in myocardial preconditioning.
    Wall TM; Sheehy R; Hartman JC
    J Pharmacol Exp Ther; 1994 Aug; 270(2):681-9. PubMed ID: 8071859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion.
    Black SC; Driscoll EM; Lucchesi BR
    Pharmacology; 1998 Jul; 57(1):35-46. PubMed ID: 9670211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reduction of infarct size and remodeling after ramipril].
    Martorana PA; Linz W; Schölkens BA
    Z Kardiol; 1994; 83 Suppl 4():63-4. PubMed ID: 7856282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution by bradykinin to the natriuretic response to the angiotensin converting enzyme inhibitor ramiprilat in spontaneously hypertensive rats.
    Sakamoto T; Chen C; Lokhandwala MF
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Jul; 350(1):84-9. PubMed ID: 7935859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model.
    Schriefer JA; Broudy EP; Hassen AH
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1034-9. PubMed ID: 8819483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide (HOE 642).
    Linz W; Albus U; Crause P; Jung W; Weichert A; Schölkens BA; Scholz W
    Clin Exp Hypertens; 1998 Oct; 20(7):733-49. PubMed ID: 9764718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation.
    Miki T; Miura T; Ura N; Ogawa T; Suzuki K; Shimamoto K; Iimura O
    J Am Coll Cardiol; 1996 Nov; 28(6):1616-22. PubMed ID: 8917279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of renal hemodynamic effect of ramiprilat to captopril; possible role of kinins.
    Chen K; Zimmerman BG
    J Pharmacol Exp Ther; 1994 Aug; 270(2):491-7. PubMed ID: 8071842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin?
    Shimada Y; Avkiran M
    J Cardiovasc Pharmacol; 1996 Mar; 27(3):428-38. PubMed ID: 8907806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.